Securities Code: 002019
Securities Abbreviation: Yifan Pharmaceutical
Announcement Number: 2026-036
Yifan Pharmaceutical Co., Ltd. announces the repurchase of company shares for cancellation. The company and all members of the board guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
Important Content Reminder:
- Type of Shares to be Repurchased: Ordinary shares (A shares) issued by the company in RMB.
- Purpose of Repurchased Shares: To cancel and reduce the company's registered capital.
- Repurchase Price Range: Not exceeding RMB 17.45 per share (inclusive).
- Total Amount of Repurchase Funds and Source of Funds: The total amount for this repurchase will not exceed RMB 120 million (inclusive) and will not be less than RMB 100 million (inclusive). The funds required for the repurchase will come from the company's own funds or self-raised funds.
- Number of Shares to be Repurchased and Proportion of Total Equity: Based on the upper limit of RMB 120 million and the upper limit of RMB 17.45 per share, approximately 6.88 million shares are expected to be repurchased, accounting for about 0.57% of the company's total equity; based on the lower limit of RMB 100 million and the upper limit of RMB 17.45 per share, approximately 5.73 million shares are expected to be repurchased, accounting for about 0.47% of the total equity. The specific number of repurchased shares will be based on the actual number repurchased at the end of the repurchase period. If the company implements capital reserve transfers, cash dividends, stock dividends, or rights issues during the repurchase period, the number of repurchased shares will be adjusted accordingly from the date of ex-rights and ex-dividends.
- Repurchase Period: No more than twelve months from the date the company's shareholders' meeting approves this repurchase plan.
- Plans of Directors, Senior Management, Controlling Shareholders, and Actual Controllers: As of the date of this announcement, there are no clear plans for increasing or decreasing holdings during the repurchase period. There are also no clear plans for reducing holdings in the next three or six months. If any related parties plan to reduce their holdings in the future, the company will strictly fulfill its information disclosure obligations in accordance with relevant laws and regulations.
Risk Warning:
- This repurchase plan is subject to approval by the shareholders' meeting, which carries the risk of not being approved.
- There is a risk that the company's stock price may exceed the upper limit of the repurchase price during the repurchase period, leading to difficulties in implementing the plan or only partial implementation.
- If the company fails to raise the necessary funds for the repurchase due to changes in external conditions or temporary operational needs, there may be risks of non-implementation or partial implementation of the repurchase plan.
- Significant changes in the company's operations, financial status, or external conditions may lead to changes or termination of the repurchase plan according to regulations.
- The repurchased shares will be used for cancellation and reduction of registered capital, which may lead to creditors requesting early repayment of debts or corresponding guarantees. The company will fulfill its information disclosure obligations in a timely manner based on the progress of the repurchase. Investors are advised to pay attention to investment risks.
According to the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Rules for the Repurchase of Shares by Listed Companies, the Self-Regulatory Guidelines for Listed Companies of the Shenzhen Stock Exchange No. 9 - Share Repurchase, and the Articles of Association of Yifan Pharmaceutical Co., Ltd., the company intends to use its own funds or self-raised funds to repurchase part of its shares through centralized bidding for cancellation and reduction of registered capital. The ninth meeting of the fifth session of the board of directors was held on May 27, 2026, and the proposal on the repurchase of company shares for cancellation was approved. The specific situation is announced as follows: